{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:46:00Z","timestamp":1775155560122,"version":"3.50.1"},"reference-count":51,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wassink Hesp Foundation","award":["#88250917"],"award-info":[{"award-number":["#88250917"]}]},{"name":"Pfizer","award":["#88250917"],"award-info":[{"award-number":["#88250917"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Among patients with advanced NSCLC, there is a group of patients with synchronous oligometastatic disease (sOMD), defined as a limited number of metastases detected at the time of diagnosis. As cachexia and sarcopenia are linked to poor survival, incorporating this information could assist clinicians in determining whether a radical treatment should be administered. In a retrospective multicenter study, including all patients with adequately staged (FDG-PET, brain imaging) sOMD according to the EORTC definition, we aimed to assess the relationship between cachexia and\/or sarcopenia and survival. Of the 439 patients that were identified between 2015 and 2021, 234 met the criteria for inclusion and were included. The median age of the cohort was 67, 52.6% were male, and the median number of metastasis was 1. Forty-six (19.7%) patients had cachexia, thirty-four (14.5%) had sarcopenia and twenty-one (9.0%) had both. With a median follow-up of 49.7 months, median PFS and OS were 8.6 and 17.3 months, respectively. Moreover, a trend toward longer PFS was found in patients without cachexia and sarcopenia compared to those with cachexia and\/or sarcopenia. In multivariate analysis, cachexia and sarcopenia were not associated with an inferior survival, irrespective of receiving radical treatment. High CRP was associated with inferior survival and could be a prognostic factor, helping the decision of clinicians in selecting patients who may benefit from the addition of LRT. However, despite the homogeneous definition of oligometastatic disease and the adequate staging, our subgroups were small. Therefore, further studies are needed to better understand our hypothesis and generating findings.<\/jats:p>","DOI":"10.3390\/cancers16010230","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T04:05:38Z","timestamp":1704341138000},"page":"230","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1493-7282","authenticated-orcid":false,"given":"Valentina","family":"Bartolomeo","sequence":"first","affiliation":[{"name":"Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"},{"name":"Department of Clinical Surgical, Diagnostic and Pediatric Sciences, Pavia University, 27100 Pavia, Italy"},{"name":"Department of Radiation Oncology (Maastro Clinic), GROW\u2014School for Oncology and Reproduction, Maastricht University Medical Center, 6229 ER Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-9169","authenticated-orcid":false,"given":"Mandy","family":"Jongbloed","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, GROW\u2014School for Oncology and Reproduction, Maastricht University Medical Center, 6229 ER Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter R. P. H.","family":"van de Worp","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NUTRIM Research Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6229 ER Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Langen","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NUTRIM Research Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6229 ER Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Degens","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Zuyderland Medical Center, 6419 PC Heerlen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E. L.","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, GROW\u2014School for Oncology and Reproduction, Maastricht University Medical Center, 6229 ER Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk K. M.","family":"de Ruysscher","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (Maastro Clinic), GROW\u2014School for Oncology and Reproduction, Maastricht University Medical Center, 6229 ER Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of Synchronous Oligometastatic Non\u2013Small Cell Lung Cancer\u2014A Consensus Report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2019.09.013","article-title":"Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion","volume":"123","author":"Hendriks","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy vs. Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jtho.2018.07.098","article-title":"Progression-Free Survival and Overall Survival beyond 5 Years of NSCLC Patients with Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)","volume":"13","author":"Wanders","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_9","unstructured":"National Comprehensive Cancer Network (2023, October 26). Non-Small Cell Lung Cancer. Version 3.2023. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO\/ESTRO Clinical Practice Guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.21037\/tlcr-20-1065","article-title":"How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: A narrative review","volume":"10","author":"Remon","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized Trial of First-Line Tyrosine Kinase Inhibitor with or without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer","volume":"115","author":"Wang","year":"2022","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jtho.2019.05.037","article-title":"Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review","volume":"14","author":"Durieux","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jtho.2018.04.035","article-title":"Sarcopenia in Resected NSCLC: Effect on Postoperative Outcomes","volume":"13","author":"Nakamura","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.21037\/tlcr-22-561","article-title":"The landscape of cancer cachexia in advanced non-small cell lung cancer: A narrative review","volume":"12","author":"Yamada","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00520-016-3287-y","article-title":"Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer\u2014Chemotherapy toxicity and prognostic value","volume":"24","author":"Srdic","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Madeddu, C., Busquets, S., Donisi, C., Lai, E., Pretta, A., L\u00f3pez-Soriano, F.J., Argil\u00e9s, J.M., Scartozzi, M., and Macci\u00f2, A. (2023). Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. Cancers, 15.","DOI":"10.3390\/cancers15041076"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1113875","DOI":"10.3389\/fnut.2023.1113875","article-title":"Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors","volume":"10","author":"Lyu","year":"2023","journal-title":"Front. Nutr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s12603-021-1633-3","article-title":"The Role of Baseline Sarcopenia Index in Predicting Chemotherapy-Induced Undesirable Effects and Mortality in Older People with Stage III or IV Non-Small Cell Lung Cancer","volume":"25","author":"Chen","year":"2021","journal-title":"J. Nutr. Health Aging"},{"key":"ref_22","first-page":"92","article-title":"Validation of the CAchexia SCOre (CASCO). Staging cancer patients: The use of miniCASCO as a simplified tool","volume":"8","author":"Betancourt","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/1759-7714.14881","article-title":"Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"14","author":"Matsuo","year":"2023","journal-title":"Thorac. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1950411","DOI":"10.1080\/2162402X.2021.1950411","article-title":"Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: A retrospective study","volume":"10","author":"Morimoto","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jcsm.12526","article-title":"Handgrip weakness, low fat-free mass, and overall survival in non-small cell lung cancer treated with curative-intent radiotherapy","volume":"11","author":"Burtin","year":"2020","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jcsm.12383","article-title":"GLIM criteria for the diagnosis of malnutrition\u2014A consensus report from the global clinical nutrition community","volume":"10","author":"Cederholm","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"775.E5","DOI":"10.1016\/j.jamda.2013.06.013","article-title":"New normative values for handgrip strength: Results from the UK Biobank","volume":"14","author":"Spruit","year":"2013","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"986236","DOI":"10.3389\/fonc.2022.986236","article-title":"Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy","volume":"12","author":"Bolte","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hasenauer, A., Forster, C., Hungerb\u00fchler, J., Perentes, J.Y., Abdelnour-Berchtold, E., Koerfer, J., Krueger, T., Becce, F., and Gonzalez, M. (2023). CT-Derived Sarcopenia and Outcomes after Thoracoscopic Pulmonary Resection for Non-Small Cell Lung Cancer. Cancers, 15.","DOI":"10.3390\/cancers15030790"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/01635581.2022.2110268","article-title":"The Effect of Sarcopenia and Metabolic PET-CT Parameters on Survival in Locally Advanced Non-Small Cell Lung Carcinoma","volume":"75","author":"Karaman","year":"2023","journal-title":"Nutr. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11882","DOI":"10.1038\/s41598-021-91449-z","article-title":"Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: A retrospective analysis","volume":"11","author":"Katsui","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11604-022-01369-9","article-title":"Role of 18F-FDG PET\/CT and sarcopenia in untreated non-small cell lung cancer with advanced stage","volume":"41","author":"Yuan","year":"2023","journal-title":"Jpn. J. Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_35","first-page":"16","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2018","journal-title":"Age Ageing"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.2147\/CMAR.S195869","article-title":"L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients","volume":"11","author":"Portal","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People","volume":"39","author":"Baeyens","year":"2010","journal-title":"Age Ageing"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0148607115604149","article-title":"Measuring Abdominal Circumference and Skeletal Muscle from a Single Cross-Sectional Computed Tomography Image","volume":"40","author":"Haus","year":"2016","journal-title":"J. Parenter. Enter. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14740\/wjon1225","article-title":"Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients with Advanced Non-Small Cell Lung Cancer","volume":"11","author":"Minami","year":"2020","journal-title":"World J. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/0284186X.2021.1978540","article-title":"The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours","volume":"60","author":"Haik","year":"2021","journal-title":"Acta Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cam4.3631","article-title":"Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer","volume":"10","author":"Nishioka","year":"2021","journal-title":"Cancer Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia\u2014Sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/1759-7714.13934","article-title":"Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancer","volume":"12","author":"Nie","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e007310","DOI":"10.1136\/jitc-2023-007310","article-title":"Increased interleukin-6\/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer","volume":"11","author":"Naqash","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","first-page":"e33234","article-title":"Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer","volume":"15","author":"Diker","year":"2023","journal-title":"Cureus"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/jcsm.12418","article-title":"Staging of nutrition disorders in non-small-cell lung cancer patients: Utility of skeletal muscle mass assessment","volume":"10","author":"Antoun","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1136\/bmjspcare-2020-002296","article-title":"The patient-generated subjective global assessment is a promising screening tool for cancer cachexia","volume":"12","author":"Cong","year":"2022","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/07853890.2022.2070660","article-title":"Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1\/PD-L1 therapy","volume":"54","author":"Minichsdorfer","year":"2022","journal-title":"Ann. Med."},{"key":"ref_49","first-page":"86","article-title":"Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer","volume":"27","author":"Menekse","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","article-title":"Forcing the vicious circle: Sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","volume":"28","author":"Bozzetti","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111345","DOI":"10.1016\/j.nut.2021.111345","article-title":"Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis","volume":"90","author":"Deng","year":"2021","journal-title":"Nutrition"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/230\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:39:41Z","timestamp":1760103581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16010230"],"URL":"https:\/\/doi.org\/10.3390\/cancers16010230","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}